Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Takeo Nomi, Masayuki Sho, +8 authors, Takahiro Akahori, Kaoru Hamada, Atsushi Kubo, Hiromichi Kanehiro, Shinji Nakamura, Koji Enomoto, Hideo Yagita, Miyuki Azuma, Yoshiyuki Nakajima. less Clin Cancer Res, 2007 Apr 04; 13(7). PMID: 17404099 Highly Cited.
|
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. Sara M Mangsbo, Linda C Sandin, +3 authors, Kerstin Anger, Alan J Korman, Angelica Loskog, Thomas H Tötterman. less J Immunother, 2010 May 07; 33(3). PMID: 20445343
|
The potential for crizotinib in non-small cell lung cancer: a perspective review. Yung-Jue Bang. Ther Adv Med Oncol, 2011 Nov 16; 3(6). PMID: 22084642 Free PMC article.
|
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Yvonne M Saenger, Jedd D Wolchok. Cancer Immun, 2008 Jan 18; 8. PMID: 18198818 Free PMC article.
|
PD-1 as a potential target in cancer therapy. David F McDermott, Michael B Atkins. Cancer Med, 2014 Jan 10; 2(5). PMID: 24403232 Free PMC article. Highly Cited. Review.
|
Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Keisuke Okudaira, Ryota Hokari, +9 authors, Yoshikazu Tsuzuki, Yoshikiyo Okada, Shunsuke Komoto, Chikako Watanabe, Chie Kurihara, Atsushi Kawaguchi, Shigeaki Nagao, Miyuki Azuma, Hideo Yagita, Soichiro Miura. less Int J Oncol, 2009 Sep 03; 35(4). PMID: 19724910
|
The blockade of immune checkpoints in cancer immunotherapy. Drew M Pardoll. Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870 Free PMC article. Highly Cited. Review.
|
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Fumiya Hirano, Katsumi Kaneko, +9 authors, Hideto Tamura, Haidong Dong, Shengdian Wang, Masao Ichikawa, Cecilia Rietz, Dallas B Flies, Julie S Lau, Gefeng Zhu, Koji Tamada, Lieping Chen. less Cancer Res, 2005 Feb 12; 65(3). PMID: 15705911 Highly Cited.
|
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. Omid Hamid, Caroline Robert, +23 authors, Adil Daud, F Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D Wolchok, Peter Hersey, Richard W Joseph, Jeffrey S Weber, Roxana Dronca, Tara C Gangadhar, Amita Patnaik, Hassane Zarour, Anthony M Joshua, Kevin Gergich, Jeroen Elassaiss-Schaap, Alain Algazi, Christine Mateus, Peter Boasberg, Paul C Tumeh, Bartosz Chmielowski, Scot W Ebbinghaus, Xiaoyun Nicole Li, S Peter Kang, Antoni Ribas. less N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846 Free PMC article. Highly Cited.
|
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Jeffrey Weber. Oncologist, 2007 Aug 04; 12(7). PMID: 17673617 Review.
|
Erlotinib in previously treated non-small-cell lung cancer. Frances A Shepherd, José Rodrigues Pereira, +17 authors, Tudor Ciuleanu, Eng Huat Tan, Vera Hirsh, Sumitra Thongprasert, Daniel Campos, Savitree Maoleekoonpiroj, Michael Smylie, Renato Martins, Maximiliano van Kooten, Mircea Dediu, Brian Findlay, Dongsheng Tu, Dianne Johnston, Andrea Bezjak, Gary Clark, Pedro Santabárbara, Lesley Seymour, National Cancer Institute of Canada Clinical Trials Group. less N Engl J Med, 2005 Jul 15; 353(2). PMID: 16014882 Highly Cited.
|
Biochemical mechanisms of cisplatin cytotoxicity. Victoria Cepeda, Miguel A Fuertes, +3 authors, Josefina Castilla, Carlos Alonso, Celia Quevedo, Jose M Pérez. less Anticancer Agents Med Chem, 2007 Feb 03; 7(1). PMID: 17266502 Highly Cited. Review.
|
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). E A Eisenhauer, P Therasse, +13 authors, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney, L Rubinstein, L Shankar, L Dodd, R Kaplan, D Lacombe, J Verweij. less Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774 Highly Cited.
|
Programmed death ligand 2 in cancer-induced immune suppression. Esdy N Rozali, Stanleyson V Hato, +2 authors, Bruce W Robinson, Richard A Lake, W Joost Lesterhuis. less Clin Dev Immunol, 2012 May 23; 2012. PMID: 22611421 Free PMC article. Highly Cited. Review.
|
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. Qifeng Zhou, Haiyan Xiao, +8 authors, Yanjun Liu, Yibing Peng, Yuan Hong, Hideo Yagita, Phillip Chandler, David H Munn, Andrew Mellor, Ning Fu, Yukai He. less J Immunol, 2010 Oct 12; 185(9). PMID: 20926790 Free PMC article.
|
Immunological response as a source to variability in drug metabolism and transport. Hege Christensen, Monica Hermann. Front Pharmacol, 2012 Mar 01; 3. PMID: 22363283 Free PMC article.
|
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. Julie R Brahmer, Scott S Tykodi, +23 authors, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi, Henry C Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith Eaton, Shuming Chen, Theresa M Salay, Suresh Alaparthy, Joseph F Grosso, Alan J Korman, Susan M Parker, Shruti Agrawal, Stacie M Goldberg, Drew M Pardoll, Ashok Gupta, Jon M Wigginton. less N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128 Free PMC article. Highly Cited.
|
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Yoshiko Iwai, Seigo Terawaki, Tasuku Honjo. Int Immunol, 2004 Dec 22; 17(2). PMID: 15611321 Highly Cited.
|
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Wenshi Wang, Roy Lau, +3 authors, Daohai Yu, Weiwei Zhu, Alan Korman, Jeffrey Weber. less Int Immunol, 2009 Aug 05; 21(9). PMID: 19651643 Free PMC article. Highly Cited.
|
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. Erin E West, Hyun-Tak Jin, +7 authors, Ata-Ur Rasheed, Pablo Penaloza-Macmaster, Sang-Jun Ha, Wendy G Tan, Ben Youngblood, Gordon J Freeman, Kendall A Smith, Rafi Ahmed. less J Clin Invest, 2013 May 17; 123(6). PMID: 23676462 Free PMC article. Highly Cited.
|
Improved survival with ipilimumab in patients with metastatic melanoma. F Stephen Hodi, Steven J O'Day, +26 authors, David F McDermott, Robert W Weber, Jeffrey A Sosman, John B Haanen, Rene Gonzalez, Caroline Robert, Dirk Schadendorf, Jessica C Hassel, Wallace Akerley, Alfons J M van den Eertwegh, Jose Lutzky, Paul Lorigan, Julia M Vaubel, Gerald P Linette, David Hogg, Christian H Ottensmeier, Celeste Lebbé, Christian Peschel, Ian Quirt, Joseph I Clark, Jedd D Wolchok, Jeffrey S Weber, Jason Tian, Michael J Yellin, Geoffrey M Nichol, Axel Hoos, Walter J Urba. less N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992 Free PMC article. Highly Cited.
|
Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Yan Zhang, Shengdong Huang, +2 authors, Dejun Gong, Yanghua Qin, Qian Shen. less Cell Mol Immunol, 2010 Jun 02; 7(5). PMID: 20514052 Free PMC article. Highly Cited.
|
PD-1 and its ligands in tolerance and immunity. Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe. Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375 Highly Cited. Review.
|
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Yoshiko Iwai, Masayoshi Ishida, +3 authors, Yoshimasa Tanaka, Taku Okazaki, Tasuku Honjo, Nagahiro Minato. less Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188 Free PMC article. Highly Cited.
|
CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications. Jang-Ik Lee, Lei Zhang, +2 authors, Angela Y Men, Leslie A Kenna, Shiew-Mei Huang. less Clin Pharmacokinet, 2010 Apr 14; 49(5). PMID: 20384392 Review.
|
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Christian Blank, Juergen Kuball, +8 authors, Simon Voelkl, Heinz Wiendl, Bernd Becker, Bernhard Walter, Otto Majdic, Thomas F Gajewski, Mathias Theobald, Reinhard Andreesen, Andreas Mackensen. less Int J Cancer, 2006 Feb 17; 119(2). PMID: 16482562 Highly Cited.
|
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. Suzanne L Topalian, F Stephen Hodi, +27 authors, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins, Philip D Leming, David R Spigel, Scott J Antonia, Leora Horn, Charles G Drake, Drew M Pardoll, Lieping Chen, William H Sharfman, Robert A Anders, Janis M Taube, Tracee L McMiller, Haiying Xu, Alan J Korman, Maria Jure-Kunkel, Shruti Agrawal, Daniel McDonald, Georgia D Kollia, Ashok Gupta, Jon M Wigginton, Mario Sznol. less N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658127 Free PMC article. Highly Cited.
|
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison. Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101 Free PMC article. Highly Cited.
|
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Tyler J Curiel, Shuang Wei, +19 authors, Haidong Dong, Xavier Alvarez, Pui Cheng, Peter Mottram, Roman Krzysiek, Keith L Knutson, Ben Daniel, Maria Carla Zimmermann, Odile David, Matthew Burow, Alan Gordon, Nina Dhurandhar, Leann Myers, Ruth Berggren, Akseli Hemminki, Ronald D Alvarez, Dominique Emilie, David T Curiel, Lieping Chen, Weiping Zou. less Nat Med, 2003 Apr 22; 9(5). PMID: 12704383 Highly Cited.
|
State of the science: an update on renal cell carcinoma. Eric Jonasch, P Andrew Futreal, +13 authors, Ian J Davis, Sean T Bailey, William Y Kim, James Brugarolas, Amato J Giaccia, Ghada Kurban, Armin Pause, Judith Frydman, Amado J Zurita, Brian I Rini, Pam Sharma, Michael B Atkins, Cheryl L Walker, W Kimryn Rathmell. less Mol Cancer Res, 2012 May 29; 10(7). PMID: 22638109 Free PMC article. Review.
|
Inhibitory B7-family molecules in the tumour microenvironment. Weiping Zou, Lieping Chen. Nat Rev Immunol, 2008 May 27; 8(6). PMID: 18500231 Highly Cited. Review.
|
Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper. Raymond Evers, Shannon Dallas, +7 authors, Leslie J Dickmann, Odette A Fahmi, Jane R Kenny, Eugenia Kraynov, Theresa Nguyen, Aarti H Patel, J Greg Slatter, Lei Zhang. less Drug Metab Dispos, 2013 Jun 25; 41(9). PMID: 23792813 Review.
|
Immunotherapy in lung cancer. M Al-Moundhri, M O'Brien, B E Souberbielle. Br J Cancer, 1998 Aug 14; 78(3). PMID: 9703271 Free PMC article. Review.
|
Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Rezaul Karim, Ekaterina S Jordanova, +5 authors, Sytse J Piersma, Gemma G Kenter, Lieping Chen, Judith M Boer, Cornelis J M Melief, Sjoerd H van der Burg. less Clin Cancer Res, 2009 Oct 15; 15(20). PMID: 19825956
|
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Mikayel Mkrtichyan, Yana G Najjar, +5 authors, Estella C Raulfs, Maher Y Abdalla, Raed Samara, Rinat Rotem-Yehudar, Larry Cook, Samir N Khleif. less Eur J Immunol, 2011 Jun 29; 41(10). PMID: 21710477 Free PMC article.
|
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Raymond M Wong, Ron R Scotland, +4 authors, Roy L Lau, Changyu Wang, Alan J Korman, W M Kast, Jeffrey S Weber. less Int Immunol, 2007 Sep 28; 19(10). PMID: 17898045
|
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Jedd D Wolchok, Axel Hoos, +9 authors, Steven O'Day, Jeffrey S Weber, Omid Hamid, Celeste Lebbé, Michele Maio, Michael Binder, Oliver Bohnsack, Geoffrey Nichol, Rachel Humphrey, F Stephen Hodi. less Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295 Highly Cited.
|
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Raanan Berger, Rinat Rotem-Yehudar, +6 authors, Gideon Slama, Shimon Landes, Abraham Kneller, Merav Leiba, Maya Koren-Michowitz, Avichai Shimoni, Arnon Nagler. less Clin Cancer Res, 2008 May 17; 14(10). PMID: 18483370 Highly Cited.
|
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Haidong Dong, Scott E Strome, +10 authors, Diva R Salomao, Hideto Tamura, Fumiya Hirano, Dallas B Flies, Patrick C Roche, Jun Lu, Gefeng Zhu, Koji Tamada, Vanda A Lennon, Esteban Celis, Lieping Chen. less Nat Med, 2002 Jul 02; 8(8). PMID: 12091876 Highly Cited.
|
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. Jacalyn Rosenblatt, Brett Glotzbecker, +10 authors, Heidi Mills, Baldev Vasir, Dimitrios Tzachanis, James D Levine, Robin M Joyce, Kerry Wellenstein, Whitney Keefe, Michael Schickler, Rinat Rotem-Yehudar, Donald Kufe, David Avigan. less J Immunother, 2011 May 18; 34(5). PMID: 21577144 Free PMC article. Highly Cited.
|
Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Martin R Jadus, Josephine Natividad, +6 authors, Anthony Mai, Yi Ouyang, Nils Lambrecht, Sandor Szabo, Lisheng Ge, Neil Hoa, Maria G Dacosta-Iyer. less Clin Dev Immunol, 2012 Aug 18; 2012. PMID: 22899945 Free PMC article. Review.
|
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Julian R Molina, Ping Yang, +2 authors, Stephen D Cassivi, Steven E Schild, Alex A Adjei. less Mayo Clin Proc, 2008 May 03; 83(5). PMID: 18452692 Free PMC article. Highly Cited. Review.
|
Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. Pasi A Jänne, Jeffrey A Engelman, Bruce E Johnson. J Clin Oncol, 2005 May 12; 23(14). PMID: 15886310 Review.
|
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Scott E Strome, Haidong Dong, +10 authors, Hideto Tamura, Stephen G Voss, Dallas B Flies, Koji Tamada, Diva Salomao, John Cheville, Fumiya Hirano, Wei Lin, Jan L Kasperbauer, Karla V Ballman, Lieping Chen. less Cancer Res, 2003 Oct 16; 63(19). PMID: 14559843 Highly Cited.
|
Nivolumab plus ipilimumab in advanced melanoma. Jedd D Wolchok, Harriet Kluger, +21 authors, Margaret K Callahan, Michael A Postow, Naiyer A Rizvi, Alexander M Lesokhin, Neil H Segal, Charlotte E Ariyan, Ruth-Ann Gordon, Kathleen Reed, Matthew M Burke, Anne Caldwell, Stephanie A Kronenberg, Blessing U Agunwamba, Xiaoling Zhang, Israel Lowy, Hector David Inzunza, William Feely, Christine E Horak, Quan Hong, Alan J Korman, Jon M Wigginton, Ashok Gupta, Mario Sznol. less N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867 Free PMC article. Highly Cited.
|
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Betty Li, Melinda VanRoey, +3 authors, Changyu Wang, Tseng-hui Timothy Chen, Alan Korman, Karin Jooss. less Clin Cancer Res, 2009 Feb 12; 15(5). PMID: 19208793
|
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Seng-Ryong Woo, Meghan E Turnis, +18 authors, Monica V Goldberg, Jaishree Bankoti, Mark Selby, Christopher J Nirschl, Matthew L Bettini, David M Gravano, Peter Vogel, Chih Long Liu, Stephanie Tangsombatvisit, Joseph F Grosso, George Netto, Matthew P Smeltzer, Alcides Chaux, Paul J Utz, Creg J Workman, Drew M Pardoll, Alan J Korman, Charles G Drake, Dario A A Vignali. less Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141 Free PMC article. Highly Cited.
|
Management of immune-related adverse events and kinetics of response with ipilimumab. Jeffrey S Weber, Katharina C Kähler, Axel Hauschild. J Clin Oncol, 2012 May 23; 30(21). PMID: 22614989 Highly Cited. Review.
|
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Don M Benson, Courtney E Bakan, +14 authors, Anjali Mishra, Craig C Hofmeister, Yvonne Efebera, Brian Becknell, Robert A Baiocchi, Jianying Zhang, Jianhua Yu, Megan K Smith, Carli N Greenfield, Pierluigi Porcu, Steven M Devine, Rinat Rotem-Yehudar, Gerard Lozanski, John C Byrd, Michael A Caligiuri. less Blood, 2010 May 13; 116(13). PMID: 20460501 Free PMC article. Highly Cited.
|
Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. W Scott Webster, R Houston Thompson, +4 authors, Kimberley J Harris, Xavier Frigola, Susan Kuntz, Brant A Inman, Haidong Dong. less J Immunol, 2007 Aug 22; 179(5). PMID: 17709500
|
Cancer despite immunosurveillance: immunoselection and immunosubversion. Laurence Zitvogel, Antoine Tesniere, Guido Kroemer. Nat Rev Immunol, 2006 Sep 16; 6(10). PMID: 16977338 Highly Cited. Review.
|